Reasons to Retain Quest Diagnostics (DGX) Stock for Now
https://www.zacks.com/stock/news/2205238/reasons-to-retain-quest-diagnostics-dgx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2205238
Jan 03, 2024 - Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.
0
3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now
https://www.zacks.com/stock/news/2202284/3-reasons-to-retain-nevro-nvro-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2202284
Dec 26, 2023 - Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.
0
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
https://www.zacks.com/stock/news/2202089/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2202089
Dec 26, 2023 - PacBio's (PACB) product development activities raise optimism about the stock.
0
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
https://www.zacks.com/stock/news/2201457/here-s-why-you-should-retain-veeva-systems-veev-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2201457
Dec 22, 2023 - Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
0
Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now
https://www.zacks.com/stock/news/2200925/reasons-to-add-integer-holdings-itgr-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200925
Dec 21, 2023 - Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
0
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
https://www.zacks.com/stock/news/2200712/reasons-to-retain-fresenius-medical-fms-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2200712
Dec 20, 2023 - Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
0
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
https://www.zacks.com/stock/news/2200160/glaukos-gkos-idose-tr-gets-fda-nod-for-glaucoma-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200160
Dec 19, 2023 - The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
0
DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump
https://www.zacks.com/stock/news/2200159/dexcom-s-dxcm-g7-cgm-connects-with-tandem-s-insulin-pump?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200159
Dec 19, 2023 - Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.
0
Molina (MOH) to Pay Lower Price for California Medicare Buyout
https://www.zacks.com/stock/news/2200048/molina-moh-to-pay-lower-price-for-california-medicare-buyout?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200048
Dec 19, 2023 - Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
0
Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now
https://www.zacks.com/stock/news/2199972/here-s-why-you-should-retain-quidelortho-qdel-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2199972
Dec 19, 2023 - QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
0